A recent report described a treatment-naïve GBM patient receiving immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4, anti-LAG3) prior to surgical resection, resulting in prolonged disease-free survival and enhanced tumor-infiltrating lymphocyte activation [19]. Here, PDCD1 is linked to glioblastoma.